Interestingly, comparing de novo and stringently characterized secondary AMLs emerging after a recorded phase of MDS, the French group discovered a molecular grouping, termed “secondary‐type AML,” defined by mutations in either SRSF2, SF3B1, U2AF1, ZRSR2, ASXL1, EZH2, BCOR, and/or STAG2 genes. This evidence concerns the gene SF3B1 and acute myeloid leukemia.